Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206682 | 0.76 | ALDH1A1 (0.50) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL29391065 | 0.74 | GABRA1 (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3259073 | 0.74 | GABRA1 (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3259068 | 0.74 | GABRA1 (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL2262850 | 0.74 | GABRA1 (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3962556 | 0.72 | NOS2 (0.50) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Ro-052921 SCHEMBL29979594 | 0.72 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Ro-052921 SCHEMBL1365706 | 0.72 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL8801062 | 0.70 | GABRA1 (0.56) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL1050699 | 0.69 | AHR (0.57) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205558-B1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | claimed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | claimed |
| EP-2205558-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | claimed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | claimed |
| WO-2009052063-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | claimed |
| EP-2205558-B1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | disclosed |
| EP-2205558-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2009052063-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | GABRA1 249/4885GABRA5 269/4885GABRA3 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.